The most frequent adverse events reported during ebastine therapy were drowsiness, headache and dry mouth, the incidence being similar to that reported in placebo recipients. Serious adverse cardiac events, observed on rare occasions with some other histamine H
1-receptor antagonists, have not been reported with ebastine and there has been no evidence of QT interval prolongation related to ebastine therapy.